title: Photodynamic therapy for premalignant lesions in DMBA-treated hamsters: a preliminary study.
abstract: OBJECTIVE
  Photodynamic therapy (PDT) involves the selective destruction of neoplastic cells through the activation of a photosensitizer by light. We have previously shown that the photosensitizer Photofrin (porfimer sodium) is selectively accumulated in transformed lesions destined to become malignant, but not yet definable histologically as precancers. The aim of this investigation was to determine if this premalignant tissue could be selectively destroyed by systemically administered Photofrin activated by 630 nm red light via an argon dye laser.
  
  
  METHODS
  The carcinogenic model used was the DMBA (9, 10 dimethyl 1,2 benzanthracene)-treated hamster cheek pouch. The animals were treated with 0.5% DMBA in acetone thrice weekly for 6 weeks (experiment I, premalignant lesions), or 12 weeks (experiment II, malignant lesions). Ten animals were in experiment I; nine animals were in experiment II. These were divided into experimental and control subgroups. The 6-week experimental group received PDT and CO2 laser incision into the DMBA-treated area. The CO2 laser was used as a promoter of neoplasia in a field that had already undergone initiation from the DMBA treatment. The control groups received either CO2 laser incision alone into the DMBA-treated field or CO2 laser incision and argon pumped dye laser treatment (without Photofrin). The 12-week experimental group received PDT after CO2 laser excision of tumors. The controls received CO2 excision alone, or CO2 excision combined with postoperative hyperthermia.
  
  
  RESULTS
  One hundred percent (three of three) of cheeks in experiment I receiving PDT developed necrosis of the treated area within 24 to 48 hours, but 0% (0 of three) subsequently developed tumors. No necrosis was seen in control cheeks receiving Photofrin without irradiation (0 of four) or irradiation without Photofrin (0 of six), and 56% (five of nine) of cheeks exposed to identical carcinogenic stimulus, without PDT, developed tumors (n = 9). In experiment II, 0% (0 of six) of cheeks receiving postoperative PDT developed tumor recurrence. In experiment II controls, 50% (three of six) of cheeks that underwent excision and hyperthermia developed tumor recurrence. In cheeks treated only with CO2 laser excision of tumors, a recurrence rate of 67% (four of six) was noted. These results were found to be statistically significant by the Student t-test on the binomial distribution (P < .01). One animal was treated with DMBA for 6 weeks, administered Photofrin, and the right cheek was irradiated and the animal was left for 30 weeks. The irradiated cheek epithelium necrosed but no cancer developed, whereas the positive control cheek developed a large cancer.
  
  
  CONCLUSIONS
  These results suggest that photodynamic therapy possesses significant potential in elimination of premalignant tissue. This could be beneficial in treating potentially premalignant lesions such as oral leukoplakia, and useful as adjunctive therapy in removal of areas of field cancerization adjacent to surgical sites.
authors.affiliation: Department of Oral and Maxillofacial Surgery, State University of New York at Buffalo, School of Dental Medicine 14214, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Kingsbury
authors.forename: W
authors.initials: W
authors.lastname: Cecere
authors.forename: T S
authors.initials: TS
authors.lastname: Mang
authors.forename: C
authors.initials: C
authors.lastname: Liebow
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002610:Cheek; D006224:Cricetinae; D017324:Hematoporphyrin Derivative / Q000627:therapeutic use; D006979:Hyperthermia, Induced; D053685:Laser Therapy; D008647:Mesocricetus; D009061:Mouth Mucosa; D009062:Mouth Neoplasms / Q000139:chemically induced / Q000188:drug therapy*; D009336:Necrosis; D010778:Photochemotherapy; D011230:Precancerous Conditions / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D015127:9,10-Dimethyl-1,2-benzanthracene; D017324:Hematoporphyrin Derivative